Big Pharmaceuticals Seek New Prescription for China Sales
(Beijing) — Multinational drugmakers are pouring hundreds of millions of dollars into new production and research operations in China to expand their foothold in the world’s fastest-growing health care market, even as the government demands sharply lower prices.
In mid-November, German drug giant Bayer AG said it would invest 100 million euros ($104 million) to double its drug packaging capacity in Beijing, creating the largest such Bayer plant in the world. Two weeks earlier, Germany’s Merck Group agreed to invest 170 million euros in a drug factory in Nantong, Jiangsu province. By 2021, it will be Merck’s largest facility outside Europe, producing 10 billion pills a year.
- 1Grisly Murder Sheds Light on Gangs Who Kill Workers for Compensation
- 2China May Introduce First Rule on Overseas Investment by Year-End
- 3Henan Considers Credit Default Swaps as Debts Mount
- 4Can China’s ‘Leather Capital’ Repay Its Environmental Debts?
- 5China Group in Front for Major New York Subway Contract